Medtronic raises FY27 adj EPS guidance to $5.94-$6.00 vs estimate

2 min read | Published on 01 Sept 2026, 04:30 PM |Updated on 01 Sept 2026, 04:31 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Medtronic raised FY27 adj EPS guidance to $5.94-$6.00, beating the $5.95 estimate
Q1 FY27 revenue rose 13.7% to $9.8 billion on strong portfolio growth
Organic revenue guidance lifted by 50 bps to 7.25%-7.75% range
Cardiovascular segment drove growth with 18.9% organic revenue increase

*this image is generated using AI for illustrative purposes only.

Medtronic plc (NYSE: MDT) raised its fiscal 2027 adjusted earnings per share guidance to a range of $5.94 to $6.00. This update places the midpoint of the company’s outlook just above the $5.95 analyst estimate, reflecting confidence in sustained operational momentum.

The medical technology leader reported first quarter fiscal 2027 revenue of $9.8 billion, an increase of 13.7% on both an as-reported and organic basis. The results, for the period ended July 31, 2026, reflect strong execution in cardiovascular and medical surgical segments. An extra fiscal week in the first quarter contributed approximately $570 million to organic growth, while favorable foreign exchange added $57 million to reported sales.

Financial Performance

Medtronic’s GAAP operating profit reached $1.76 billion, up 22.1% year-over-year, with operating margins expanding 120 basis points to 18.1%. On a non-GAAP basis, operating profit was $2.32 billion, representing a 14.9% increase and a stable operating margin of 23.7%.

GAAP net income attributable to Medtronic rose 41.4% to $1.47 billion, driven by higher operating profits and non-operating income. Non-GAAP diluted earnings per share (EPS) came in at $1.45, exceeding the company’s previous guidance range.

Metric	Q1 FY27	Q1 FY26	Change
Revenue	$9.8 billion	$8.6 billion	+13.7%
GAAP Operating Profit	$1.76 billion	$1.45 billion	+22.1%
GAAP Operating Margin	18.1%	16.8%	+120 bps
Non-GAAP Diluted EPS	$1.45	$1.26	+15.1%

Portfolio Growth Drivers

The cardiovascular portfolio led the charge with organic revenue growth of 18.9%, reaching $3.93 billion. This performance was anchored by high-20s growth in Electrophysiology Therapies and double-digit gains in Interventional Cardiology and Peripheral Vascular Health.

Neuroscience revenue grew 9.3% organically to $2.68 billion, supported by low-double-digit increases in Cranial and Spinal Technologies. The Medical Surgical portfolio also performed strongly, posting 10.2% organic growth to $2.28 billion, led by mid-teens growth in Acute Care and Monitoring.

Guidance and Strategic Moves

Management raised its fiscal 2027 organic revenue growth guidance by 50 basis points to a range of 7.25% to 7.75%, up from the prior estimate of 6.75% to 7.25%. Concurrently, the full-year non-GAAP diluted EPS guidance was increased to $5.94 to $6.00 from $5.90 to $6.00. This revised guidance stands against an analyst estimate of $5.95.

Strategically, Medtronic announced expanded CE Mark indications for its Affera Mapping and Ablation System and completed acquisitions of Scientia Vascular and SPR Therapeutics. The company also secured a strategic partnership with Cornerstone Robotics to expand access to robotic-assisted surgery.

What the Numbers Show

A significant divergence exists between GAAP and non-GAAP profitability metrics due to substantial non-cash charges. While GAAP operating margins expanded by 120 basis points to 18.1%, non-GAAP margins remained flat at 23.7%. This indicates that the top-line revenue growth of 13.7% translated directly into operational efficiency, but GAAP results were weighed down by $412 million in amortization of intangible assets and $72 million in restructuring charges, which are excluded from the non-GAAP view.

Free cash flow surged to $1.29 billion, more than doubling the $584 million recorded in the prior-year period, highlighting improved cash conversion despite heavy investment in acquisitions totaling $1.16 billion.

How will the integration of Scientia Vascular and SPR Therapeutics impact Medtronic's long-term margin profile and R&D efficiency?

What is the expected timeline for revenue contribution from the new Cornerstone Robotics partnership in the Medical Surgical segment?

Can Medtronic sustain its 18.9% cardiovascular organic growth rate given potential regulatory headwinds or reimbursement pressures?

Strategic Rationale

The partnership supports the next generation of innovation in structural heart care. By securing this option, Medtronic aims to enhance its capabilities in treating patients with more complex anatomical challenges during TAVR interventions.

What the Numbers Show

The source material does not disclose specific financial terms, such as the investment amount or equity stake acquired. Consequently, no quantitative analysis of valuation or immediate financial impact can be derived from the filing.

How might this investment accelerate Medtronic's pipeline for treating high-risk TAVR patients compared to competitors like Edwards Lifesciences?

What are the potential regulatory hurdles and timelines for integrating Pi-Cardia's leaflet modification technology into Medtronic's existing valve systems?

Could this strategic option lead to a full acquisition of Pi-Cardia, and how would that impact Medtronic's R&D spending and balance sheet in the medium term?